GLOBALT Investments LLC GA Reduces Position in AstraZeneca PLC (NASDAQ:AZN)

GLOBALT Investments LLC GA lowered its position in AstraZeneca PLC (NASDAQ:AZN) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,485 shares of the company’s stock after selling 2,747 shares during the period. GLOBALT Investments LLC GA’s holdings in AstraZeneca were worth $5,414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AZN. State Board of Administration of Florida Retirement System purchased a new stake in shares of AstraZeneca during the first quarter valued at $1,524,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in AstraZeneca by 2.7% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 34,658 shares of the company’s stock valued at $2,348,000 after buying an additional 914 shares during the period. Rockport Wealth LLC bought a new position in AstraZeneca in the 1st quarter worth about $370,000. O Shaughnessy Asset Management LLC increased its position in shares of AstraZeneca by 17.9% during the first quarter. O Shaughnessy Asset Management LLC now owns 111,659 shares of the company’s stock worth $7,565,000 after acquiring an additional 16,966 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of AstraZeneca during the first quarter valued at approximately $213,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen increased their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Price Performance

Shares of AZN opened at $63.23 on Monday. The company has a 50 day moving average of $75.03 and a two-hundred day moving average of $78.23. The company has a market cap of $196.05 billion, a price-to-earnings ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the business posted $0.87 earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.